New Autonomous ITVS to Boost Operational Efficiency at Jebel Ali Port in Deal Between DP World, UAE Region and DGWORLD
Leading trade enabler, DP World, UAE Region and the autonomous vehicle, robotics and AI specialist DGWorld has entered a contractual agreement to equip Jebel Ali Port with a fleet of Autonomous Internal Terminal Vehicles (AITVs), including all related integrations in the existing operation processes and infrastructures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005515/en/
Mohammed Al Muallem, CEO and Managing Director, DP World, UAE Region (Photo: AETOSWire)
DP World, UAE Region once again manifests its leadership and visionary role by introducing autonomous vehicles and related technologies into their daily operations, which supports their initiatives and strategy of introducing digitalization and newest technologies as the new global standard for traditional port operations, supply chains and to enable the future of trade.
The contract signed between the two sides states, DGWorld will deliver and integrate their autonomous technology at the existing ITV fleet in multiple phases, with the goal to further increase the overall efficiency of the terminal and reduce the overall size of the currently used fleet, at the same time.
Mohammed Al Muallem, CEO and Managing Director, DP World, UAE Region, said: "At DP World, UAE Region, we employ today's frontline technologies such as robotics, automation, Internet of Things, Big Data, virtual reality and cybersecurity to build and sustain our efficiencies. As a trade enabler, technology has powered and underpinned our capabilities as an essential economic service at a time when the UAE needs us most. Digital technology will continue to drive smart trade for DP World, UAE Region and help us create a better future for all."
Bilal Al-Zoubi – DGWorld Founder & CEO, added: “We are so proud of the Trust received by DP World, one of the leading global Port Operators and smart trade enablers, to work under their umbrella to deliver these advanced AI, Robotics & Autonomous Technologies. Following the visionary leadership of DP World and Dubai to be one most advanced & smartest Ports as well as City in the world, we are investing heavily in the best Minds, Practices and Resources to develop those Applications & Technologies to match their operational requirements based on the Highest International Standards and now we are moving stronger to expand our current operations locally and globally with the great support of DP World and the Dubai - UAE Government.”
Previous trials of this new technology have shown that it is capable of unlocking new potentials for efficient and economical automation of already existing Container Terminals in combination with the intensive utilization of new AI-based software solutions, which have been integrated by the teams of both parties, jointly.
For more information please visit: www.dgworld.com
View source version on dgworld.com: https://www.dgworld.com/Press-Details/NEW-AUTONOMOUS-ITVs-TO-BOOST-OPERATIONAL-EFFICIENCY-AT-JEBEL-ALI-PORT-IN-DEAL-BETWEEN-DP-WORLD--UAE-REGION-AND-DGWORLD/26
Find us on LinkedIn: https://www.linkedin.com/in/dgworld/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005515/en/
Contact information
DGWorld Media Team
Eng. Yasmin Enazi
Projects Director
M: +971 50 6600513
Email: yasmin@dgworld.com
Mr. Gautam Ahuja
Commercial Director
M: +971 50 6600512
Email: gautam@dgworld.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom